Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

LezGoh Nov. 14 at 1:42 PM

$BEAM $PTGX $SRPT $VKTX it’ll be $SRPT imo. That’s close to getting acquired look at funds loading up.

0 · Reply

blueb22 Nov. 14 at 1:39 PM

$VKTX $PTGX $SRPT $BEAM - Merck buying Cidara for $9.2 B - at $220, which is 115 premium to Yesterday's price, and stock was just $25 till July. Wow!!! Whoever was holding prior to July will make 9x. Even with this BO news Biotechs are down due to bad overall market and as always panic selling and short attack. This Merck BO should suggest VKTX should atleast get $120-140 in BO deal for these Obesity advance pipeline and MASH . I think it is coming. Other Biotechs like SRPT and BEAM should also get fat premium offers. J&J was in talk to buy PTGX last month but then there is no update, I think they will be bought in $120-130 range soon (should be even more)

0 · Reply

HedgeAlerts Nov. 14 at 7:45 AM

Hedge Alert Live - Protect Your Portfolio Contract: $BEAM $21.00 Put · NOV 21, 2025 Exp Entry Price: $0.64 - $0.90 Exit Price Target: $1.14 Profit Margin: +78% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

SquidGainz Nov. 14 at 12:46 AM

$WBTN $SCNX $LFMD $BEAM 1

0 · Reply

Noobnr1 Nov. 13 at 4:15 PM

$BEAM C’mon let’s go again thanks $PFE $NYXH numbers after hours 🚀🚀🚀 $PHAR 🥇🐇

0 · Reply

Elamenape2 Nov. 13 at 3:28 PM

$PRME $BEAM THE PATH FORWARD

0 · Reply

biotech Nov. 13 at 3:13 PM

$SGMO $XBI $BEAM $PRME

0 · Reply

APman Nov. 13 at 3:12 PM

$NTLA $PRME $CRSP $BEAM Maybe Beam will pull us all out of the doldrums.

1 · Reply

MaxDanger Nov. 13 at 1:40 AM

$NTLA FDA just published in @NEJM a new "plausible mechanism pathway" for personalised therapies! Actually detailed by Makary & Prasad...and inspired by Baby KJ's CRISPR success. Companies will be allowed to leverage 'platform data' (e.g, safety and scientific info from prior therapies) to streamline submissions for similar bespoke treatments, potentially enabling MA and reimbursement from gov't and insurers to expedite approvals. Post-approval safety monitoring to add rigour to the new pathway i.e. it will be a requirement to gather RWE tracking long-term safety, off-target edits and developmental outcomes. For gene editors like $NTLA, $CRSP, $BEAM and $PRME potential for accelerated pipelines, cost savings, and broader market access via reusable editing data.

0 · Reply

Windytimes Nov. 12 at 4:44 PM

$PRME here is the reality, the sector cooled off a couple of weeks and the shorts started piling on, this went on a tear and now it’s retracing hopefully it holds around this price range and forms a base. The sector popped on the back of the billion plus acquisition of Verv- which uses $BEAM base editing tech. Prime will see its day- and most likely be the next billion + acquisition. Everything else is just noise.

0 · Reply

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 10 days ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 11 days ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Oct 22, 2025, 10:19 AM EDT - 23 days ago

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Sep 9, 2025, 9:54 AM EDT - 2 months ago

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 4:51 AM EDT - 2 months ago

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 3, 2025, 8:38 PM EDT - 2 months ago

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 20, 2025, 10:07 AM EDT - 5 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 6 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 6 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 6 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 6 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 6 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 8 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 8 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 8 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 8 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 8 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 9 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 10 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 10 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 10 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 1 year ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 1 year ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Feb 27, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

LezGoh Nov. 14 at 1:42 PM

$BEAM $PTGX $SRPT $VKTX it’ll be $SRPT imo. That’s close to getting acquired look at funds loading up.

0 · Reply

blueb22 Nov. 14 at 1:39 PM

0 · Reply

HedgeAlerts Nov. 14 at 7:45 AM

0 · Reply

SquidGainz Nov. 14 at 12:46 AM

$WBTN $SCNX $LFMD $BEAM 1

0 · Reply

Noobnr1 Nov. 13 at 4:15 PM

$BEAM C’mon let’s go again thanks $PFE $NYXH numbers after hours 🚀🚀🚀 $PHAR 🥇🐇

0 · Reply

Elamenape2 Nov. 13 at 3:28 PM

$PRME $BEAM THE PATH FORWARD

0 · Reply

biotech Nov. 13 at 3:13 PM

$SGMO $XBI $BEAM $PRME

0 · Reply

APman Nov. 13 at 3:12 PM

$NTLA $PRME $CRSP $BEAM Maybe Beam will pull us all out of the doldrums.

1 · Reply

MaxDanger Nov. 13 at 1:40 AM

0 · Reply

Windytimes Nov. 12 at 4:44 PM

0 · Reply

blueb22 Nov. 12 at 7:02 AM

$SRPT - sorry this one was for $BEAM For SRPT it is Roche who would buy SRPT eventually (and hopefully soon)

0 · Reply

mankind1 Nov. 11 at 8:45 PM

$BEAM beaming

0 · Reply

blueb22 Nov. 10 at 5:27 PM

$VKTX $SRPT $PTGX $BEAM $NTLA - In JPM Healthcare conferences 13-14 Jan 2026, featured sessions include "Pharma's Big Bet and the Resurgence of M&A", "Next-gen Partnerships: Unlocking Speed, Scale, and Value in Clinical Development", and most important for VKTX (and metabolic players) is "GLP-1s and the Next Waves in Obesity Therapies" Will be very interesting. And bullish for VKTX

0 · Reply

JohnnyUtah309 Nov. 10 at 2:34 PM

$BEAM

0 · Reply

LiquidThetaOptions Nov. 9 at 12:38 AM

💎 LiquidTheta® Live Actionable Trade Asset: $BEAM Contracts: $BEAM January 15, 2027 $25 Calls Scale in: $6.86- $8.39 Scale out: $26.69-$45.75 Profit Potential : 435% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

blueb22 Nov. 8 at 2:04 AM

$BEAM - Beam is a solid company with very strong balancesheet ($1.1B cash) and very promising Base Editing Crispr gene therapy and platform with large indication of SCD with 3 wave comprehenive development strategy, and two other mid-Stage programs, early discovery partnerships with Pfizer and Epelis etc. But it is very hard for Biotech to go alone in this crazy market and we have seen dramatic stock price/market crash of good companies like Sarepta and very recently Intellia (and something similar for Viking with Obesity drug development). So, Beam should try to merge with larger Pharma for best value for patients (for rapid and expansive drug pipeline development) and for shareholders. Period. Best candidates are Lilly (as they bought Verve and so Beam will add big pie to their gene therapy portfolio - and they are indirectly partners) OR Pfizer (as they are discovering three or four undisclosed drug candidates for Pfizer and end of that contract is nearing)

0 · Reply

PorkchopSquats Nov. 7 at 4:56 PM

$CRSP $BEAM $PRME $NTLA FDA RELEASE THOSE DAMN GUIDELINES.

0 · Reply

JohnnyUtah309 Nov. 6 at 3:45 PM

$BEAM

0 · Reply

JohnnyUtah309 Nov. 6 at 9:25 AM

$BEAM

0 · Reply

jewell69 Nov. 6 at 12:31 AM

$BEAM at least it isn't gene therapy, bottom line profit 19.53 on several trades 10/31/2025 Sell Trade Details BEAM BEAM THERAPEUTICS INC 103 $26.0031 $0.02 $2.X,678.30 10/29/2025 Buy Trade Details BEAM BEAM THERAPEUTICS INC 52 $25.97 -$1.X,350.44 10/28/2025 Buy Trade Details BEAM BEAM THERAPEUTICS INC 51 $26.43 -$1.X,347.93 10/28/2025 Sell Trade Details BEAM BEAM THERAPEUTICS INC 87 $26.48 $0.01 $2.X,303.75 10/28/2025 Buy Trade Details BEAM BEAM THERAPEUTICS INC 87 $26.19 -$2.X,278.53 10/27/2025 Sell Trade Details BEAM BEAM THERAPEUTICS INC 86 $26.4473 $0.01 $2.X,274.46 10/27/2025 Buy Trade Details BEAM BEAM THERAPEUTICS INC 86 $26.28 -$2.X,260.08 page total 19.53 11/5 close 23.07

0 · Reply

blueb22 Nov. 5 at 7:55 AM

$BEAM - I didn't knew how much of Orbital Therapeutics owned by BEAM , and now Q3 mentioned they own 17% (75m shares), and that translates into $255M cash!!! When BMY buyout transaction closes (which should be relatively soon). Not sure how much BEAM had recorded value of this stake in balancesheet, it must have atleast gone up by 100%, meaning roughly $125M profit!!! And increase in cash!

0 · Reply

Elamenape2 Nov. 5 at 4:55 AM

$BEAM

0 · Reply

Market Cap	2.22B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.10%
Debt to Equity Ratio	0.00

Volume	3,648,700
Avg Vol	2,600,328
Day's Range	N/A - N/A
Shares Out	101.48M
Stochastic %K	12%
Beta	2.40
Analysts	Strong Sell
Price Target	$46.62